Healthcare >> CEO Interviews >> December 18, 2000
Prior to the formation of Curis in July 2000, DR. DOROS PLATIKA served
as President and Chief Executive Officer and as a member of the Board of
Directors of Ontogeny, a precursor company to Curis, since July 1996.
From June 1993 to June 1996, Dr. Platika was employed by Progenitor,
Inc., a biotechnology company, most recently as Executive Vice President
responsible for research and development. Dr. Platika completed
residencies in medicine and neurology at Massachusetts General Hospital,
where he became Chief Resident. He did postdoctoral study at the
Whitehead Institute, Massachusetts Institute of Technology and at
Massachusetts General Hospital in association with Harvard Medical
School. Dr. Platika served on the faculties of Harvard Medical School
and Albert Einstein College of Medicine, where he was the head of gene
therapy. Dr. Platika completed his MD at the State University of New
York at Stony Brook School Of Medicine and received his BA from Reed
College. In August 2000, Dr. Platika was elected to the Board of V.I.
Technologies, Inc. Profile
Dr. Platika: The focus of Curis, Inc. is regenerative medicine. The
therapeutic approach in regenerative medicine is
